IP Library Granted Patent US 10,561,604
Granted Patent B2
US 10,561,604 · App. 15/671,727 · Granted Feb 18, 2020

Pharmaceutical composition comprising botulinum, a non ionic surfactant, sodium chloride and sucrose

Inventors: Paul Webb (Wrexham, GB); Mary White (Wrexham, GB); Julie Partington (Wrexham, GB)
Assignee: IPSEN BIOPHARM LIMITED
A61K9/0019A61K9/19A61K38/4886A61K38/4893A61K47/26C12Y304/24069
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,561,604
App. No.
15/671,727
Granted
Feb 18, 2020
Kind
B2
Abstract

Solid and liquid pharmaceutical compositions comprising botulinum neurotoxin complex or high purity botulinum neurotoxin and a surfactant. The composition may comprise a crystalline agent.

Claims (12)

1. A pharmaceutical composition comprising:

(a) a high purity botulinum neurotoxin or a complex comprising botulinum neurotoxin, wherein the botulinum neurotoxin is of type A, B, C, D, E, F, or G; and

(b) a surfactant;

wherein the composition is a solid or liquid composition and does not comprise albumin or a polysaccharide.

2. The composition of claim 1 , further comprising a sodium chloride.

3. The composition of claim 1 , further comprising a buffer capable of maintaining an aqueous solution at a pH between 5.5 and 7.5.

4. The composition of claim 3 , wherein the buffer is capable of maintaining an aqueous solution at a pH between 5.8 and 7.0.

5. The composition of claim 1 , further comprising a disaccharide.

6. The composition of claim 5 , wherein the disaccharide is sucrose, trehalose, lactose, or mannitol.

7. The composition of claim 1 , comprising a complex comprising botulinum neurotoxin type A.

8. The composition of claim 1 , comprising high purity botulinum neurotoxin type A.

9. The composition of claim 1 , wherein the surfactant is polysorbate 80.

Assignments (3)
CHANGE OF NAME Recorded Dec 18, 2017
From: IPSEN DEVELOPMENTS LIMITED
To: IPSEN BIOPHARM LIMITED
Reel/Frame 044419/0600 →
CHANGE OF NAME Recorded Sep 11, 2017
From: IPSEN LIMITED
To: IPSEN DEVELOPMENTS LIMITED
Reel/Frame 043856/0285 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 7, 2017
From: WEBB, PAUL; WHITE, MARY; PARTINGTON, JULIE
To: IPSEN LIMITED
Reel/Frame 043524/0409 →
Priority Claims (1)
GB 0415491.0 · Jul 12, 2004 · national
Continuity (3)
Continuation 14810975 · Jul 28, 2015
Continuation 11632156
Related Publication 20170348226A1 · Dec 7, 2017
Cited By (1)
US 12,377,137